Upper limb physiotherapy and hand therapy in EB

EB Treatment Momentum

Epidermolysis bullosa, a rare genetic disorder causing fragile skin that blisters from minor friction, has seen rapid advancements in treatment options. In 2025, the FDA approved Zevaskyn, the first autologous gene-edited cell therapy for recessive dystrophic EB, enabling better wound closure and reducing pain. This follows expansions to Vyjuvek, a topical gene therapy, allowing use from birth and home application. These developments address the core issue of collagen deficiency, particularly in types like dystrophic EB where skin layers fail to anchor properly.

Hands and upper limbs suffer disproportionately in EB, with repeated blistering leading to scarring, contractures, and pseudosyndactyly—fused digits resembling mittens. This impacts daily activities, from gripping objects to self-care, affecting roughly 500,000 people worldwide, though severe forms strike 1 in 20,000 births. Children with recessive dystrophic EB often develop these deformities early, with 98% showing hand involvement by adulthood. Physiotherapy focuses on gentle range-of-motion exercises and splinting to delay progression, but the fragility of skin poses a constant risk of new wounds during sessions.

The real-world stakes are high: untreated contractures can lead to permanent disability, increased infection risks, and squamous cell carcinoma, shortening life expectancy to under 30 years in severe cases. Costs for emerging gene therapies exceed $1 million per patient annually in some estimates, straining healthcare systems. Deadlines loom with NICE's Vyjuvek decision expected in July 2026, potentially expanding UK access amid regulatory reforms to accelerate approvals. Inaction risks escalating surgical needs, with procedures costing $50,000-$100,000 each and recurrence within 2-5 years common.

Non-obvious tensions include balancing aggressive physiotherapy against skin trauma, where overzealous stretching might worsen blistering. Stakeholder divides emerge: pharmaceutical firms push curative gene edits, while patient groups like DEBRA advocate repurposed drugs via trials like ART-EB launched in November 2025, testing affordable anti-inflammatories. Surprising data shows some therapies yielding 8-year wound durability, yet small patient pools—fewer than 5,000 U.S. cases—slow trials, highlighting ethical trade-offs in prioritizing rare disease research.